文献速递流行病学与生物统计临床试验与 GCP

重新审视种族与射血分数降低的心力衰竭中RAS阻滞的获益:随机临床试验的荟萃分析

Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
PubMed 文献 · JAMA · 2024-01-01

该荟萃分析基于个体参与者数据,纳入3项安慰剂对照RAS抑制剂单药治疗试验(n=8825,黑人占9.9%),评估RAS阻滞对黑人及非黑人HFrEF患者心血管结局的影响。结果显示,RAS阻滞降低死亡风险的获益在两组相似,黑人患者心力衰竭住院的相对风险降低较小,但因该结局发生率更高,绝对获益与非黑人患者相当。

要点

  • RAS阻滞降低死亡风险的获益在黑人及非黑人HFrEF患者中相似。
  • 黑人患者心力衰竭住院的相对风险降低较小,但绝对获益与非黑人患者相当。
  • 支持性分析纳入2项在ACEI基础上加用ARB的试验(n=16383),结果一致。

核心结论

  • RAS阻滞降低死亡风险的获益在黑人及非黑人HFrEF患者中相似。
  • 尽管黑人患者心力衰竭住院的相对风险降低较小,但因该结局发生率更高,绝对获益与非黑人患者相当。

研究设计与样本

  • 研究为随机临床试验的荟萃分析,检索MEDLINE和Embase数据库至2023年12月31日。
  • 纳入在成人HFrEF患者中调查RAS阻滞对心血管结局影响的随机试验,且试验入组了黑人和非黑人患者。
  • 提取个体参与者数据,遵循PRISMA-IPD报告指南,采用混合效应模型的一阶段法估计效应。
  • 主要分析基于3项安慰剂对照RAS抑制剂单药治疗试验,纳入8825例患者(黑人占9.9%)。
  • 支持性分析纳入2项在背景ACEI治疗基础上加用ARB的试验(n=16383)。

主要发现

  • 主要复合终点(首次心力衰竭住院或心血管死亡)的HR:黑人患者为0.84(95%CI 0.69-1.03),非黑人患者为0.73(95%CI 0.67-0.79),交互作用P=0.14。
  • 首次心力衰竭住院的HR:黑人患者为0.89(95%CI 0.70-1.13),非黑人患者为0.62(95%CI 0.56-0.69),交互作用P=0.006。
  • 心血管死亡的HR:黑人患者为0.83(95%CI 0.65-1.07),非黑人患者为0.84(95%CI 0.77-0.93),交互作用P=0.99。
  • 心力衰竭总住院和心血管死亡的率比:黑人患者为0.82(95%CI 0.66-1.02),非黑人患者为0.72(95%CI 0.66-0.80),交互作用P=0.27。
  • 黑人患者死亡和心力衰竭住院率显著高于非黑人患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF). OBJECTIVE: To determine whether the effects of RAS blockers on cardiovascular outcomes differ between Black patients and non-Black patients with HFrEF. DATA SOURCES: MEDLINE and Embase databases through December 31, 2023. STUDY SELECTION: Randomized trials investigating the effect of RAS blockers on cardiovascular outcomes in adults with HFrEF that enrolled Black and non-Black patients. DATA EXTRACTION AND SYNTHESIS: Individual-participant data were extracted following Preferred Reporting Items for Systematic Reviews and Meta-analyses Independent Personal Data (PRISMA-IPD) reporting guidelines. Effects were estimated using a mixed-effects model using a 1-stage approach. MAIN OUTCOME AND MEASURE: The primary outcome was first hospitalization for HF or cardiovascular death. RESULTS: The primary analysis, based on the 3 placebo-controlled RAS inhibitor monotherapy trials, included 8825 patients (9.9% Black). Rates of death and hospitalization for HF were substantially higher in Black than non-Black patients. The hazard ratio (HR) for RAS blockade vs placebo for the primary composite was 0.84 (95% CI, 0.69-1.03) in Black patients and 0.73 (95% CI, 0.67-0.79) in non-Black patients (P for interaction = .14). The HR for first HF hospitalization was 0.89 (95% CI, 0.70-1.13) in Black patients and 0.62 (95% CI, 0.56-0.69) in non-Black patients (P for interaction = .006). Conversely, the corresponding HRs for cardiovascular death were 0.83 (95% CI, 0.65-1.07) and 0.84 (95% CI, 0.77-0.93), respectively (P for interaction = .99). For total hospitalizations for HF and cardiovascular deaths, the corresponding rate ratios were 0.82 (95% CI, 0.66-1.02) and 0.72 (95% CI, 0.66-0.80), respectively (P for interaction = .27). The supportive analyses including the 2 trials adding an angiotensin receptor blocker to background angiotensin-converting enzyme inhibitor treatment (n = 16 383) gave consistent findings. CONCLUSIONS AND RELEVANCE: The mortality benefit from RAS blockade was similar in Black and non-Black patients. Despite the smaller relative risk reduction in hospitalization for HF with RAS blockade in Black patients, the absolute benefit in Black patients was comparable with non-Black patients because of the greater incidence of this outcome in Black patients.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Shen L, Lee MMY, Jhund PS, et al. Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. JAMA. 2024. PMID: 38809561. doi:10.1001/jama.2024.6774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。